Follow us

Diaceutics (DXRX)

Diaceutics (AIM: DXRX), 2021 Capital Markets Day

24 June 2021

Diaceutics Group CEO, Peter Keeling, and members of the senior management team provide an update on strategy, a demonstration of the DXRX SaaS platform and an expert industry panel discuss their views on the diagnostics market for precision medicine.

00:18 – Introduction by Deborah Davis Non-Executive Chair

06:28 – Overview of Diacuetics, Peter Keeling Founder and CEO

14:38 – Introduction to DXRX, Ryan Keeling Chief Innovation Officer

47:14 – Industry expert panel discussion Led by Susanne Munksted, Chief Precision Officer.

1:15:21 – Q&A

1:34:38 – Our opportunity & strategic roadmap, Peter Keeling Founder and CEO

1:41:31 – Business model & KPIs, Philip White CFO

1:49:10 – Conclusion, Peter Keeling Founder and CEO

1:50:35 – Q&A

1:59:56 – Closing remarks, Peter Keeling Founder and CEO

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world’s leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX – The Diagnostic Network®.
DXRX is the world’s first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Listen on the go


PIWORLD provides investors with the latest news and insight about listed companies and their management through either live or recorded investor presentations, management interviews, Capital Market Days and corporate overviews, together with interviews with leading fund managers or esteemed private investors in the small cap world.

Our Services

PIWORLD delivers high quality audio and video content to present anything from full-year & interim results to Capital Markets Days and corporate overviews. We bridge the gap between listed companies and the private investor community, who drive the share price and provide liquidity, providing a time and cost effective medium to reach this diverse and important audience.